Background/aim: The aim of this multi-center retrospective study was to investigate the results of stereotactic body radiotherapy (SBRT) for pulmonary oligometastases from esophageal cancer.
Patients And Methods: Oligometastases from the esophagus were identified from a dataset of a Japanese survey. The Kaplan-Meier method and Cox regression were applied to perform analyses.
Results: A total of 114 patients with 132 pulmonary oligometastases were collected. The 3-year local control rate, freedom from further metastasis (FFFM) rate and overall survival (OS) rate were 70.2%, 25.3% and 37.5%, respectively. Performance status (PS) (PS 1 vs. PS 0, p<0.01), disease-free interval (p=0.03) and history of local therapy for metastasis (p=0.01) had significant relationships with FFFM and only PS was an independent prognostic factor for OS (PS 1 vs. PS 0, p=0.02; PS 2-3 vs. PS 0, p=0.04).
Conclusion: SBRT for pulmonary oligometastases from esophageal cancer provided good local control and survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.14164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary Stereotactic Body Radiotherapy of Oligometastatic Head-and-Neck Squamous Cell Carcinoma - A multicenter retrospective study.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany; Comprehensive Cancer Center Central Germany, Partner Site Leipzig, Leipzig, Germany; Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK), Partner site DKTK, Freiburg, Germany. Electronic address:
Article Synopsis
- The study evaluates the effectiveness of stereotactic body radiotherapy (SBRT) in improving survival outcomes for patients with oligometastatic head-and-neck squamous cell carcinoma (HNSCC) and pulmonary metastases across 16 international centers.
- Out of 178 patients treated, the median overall survival was 33 months, while progression-free survival was 9 months, with low rates of local failure and minimal severe toxicity reported.
- Factors influencing survival included age and sex, with older patients and females having worse outcomes, while a longer time between HNSCC diagnosis and SBRT treatment was linked to better survival rates.
Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529).
Radiat Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Article Synopsis
- This study explored the effectiveness and safety of combining chemoradiotherapy (CRT) with local consolidative therapy (LCT) for patients with Stage IV non-small cell lung cancer (NSCLC) and oligometastases.
- During the Phase II trial involving 19 patients, the treatment resulted in a 58% response rate, median progression-free survival of 8.6 months, and a two-year survival rate of 68.4%.
- The findings suggest that this aggressive treatment approach may prolong survival and improve local control without severe adverse events.
Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.
PLoS One
January 2025
Colorectal Cancer Center, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
This study aimed to identify radiotherapy dosimetric parameters related to local failure (LF)-free survival (LFFS) in patients with lung and liver oligometastases from colorectal cancer treated with stereotactic body radiotherapy (SBRT). We analyzed 75 oligometastatic lesions in 55 patients treated with SBRT between January 2014 and December 2021. There was no constraint or intentional increase in maximum dose.
View Article and Find Full Text PDFEducation and Training Needs of Health Care Professionals in the Philippines Encountering Patients with Lung Oligometastatic Cancers.
Curr Oncol
December 2024
Department of Radiation Oncology, Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON M5G 2M9, Canada.
This study aimed to examine the education and training needs of health care practitioners (HCPs) in the Philippines who encounter lung oligometastatic cancer patients. Lung oligometastatic disease is among the most common sites for cancer spread and has the most established practices for treating oligometastases. A modified version of the Hennessy-Hicks Training Needs Assessment Questionnaire was administered online to HCPs working in private and public centers in the Philippines.
View Article and Find Full Text PDFLong-term outcomes of surgical treatment of non-small cell lung cancer with oligometastatic disease involving only the brain in the era of PET/CT.
J Cardiothorac Surg
December 2024
Department of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Background: The prognosis of patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) has been improving owing to advancements in imaging techniques and new treatment approaches such as tyrosine kinase inhibitors. This study aimed to investigate the long-term outcomes, including the clinical course after recurrence, of patients with synchronous oligometastatic NSCLC with only brain metastases, treated with bifocal treatment.
Methods: We retrospectively analyzed 22 patients with clinical T1-4 and N0-1 NSCLC with synchronous brain metastases who were diagnosed by preoperative PET/CT and brain CT or MRI and underwent pulmonary resection for the primary site and surgery or radiation therapy for brain metastases at our institution from 2005 to 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!